Trial intelligence / Profile preview

ITI-007 for Agitation in Dementia

NCT02817906Phase 3Terminated

Sponsor
Intra-Cellular Therapies
Start
Aug 2016
Primary completion
Jan 2019
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of lumateperone in agitation, sponsored by Intra-Cellular Therapies. Started Aug 2016; status: terminated.

02

Drugs

lumateperone
03

Conditions

agitation

Beyond the preview

Go deeper on NCT02817906.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02817906.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call